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Introduction: Individuals who are younger, have a high socioeco-
nomic background and/or have a healthy lifestyle are more inclined 
to participate in screening trials. This form of bias may affect the 
generalizability of study results to the target population. This study 
aimed to investigate the generalizability of the NELSON lung cancer 
screening trial to the Dutch population.
Methods: People at high risk for developing lung cancer were identi-
fied by sending a health questionnaire to 606,409 persons aged 50–74 
years, based on population registries. Eligible subjects received an 
invitation to participate (n = 30,051). 15,822 subjects agreed to par-
ticipate and were randomized, whereas 15,137 did not respond (so-
called eligible nonresponders). Baseline characteristics and mortality 
profiles were compared between control group participants and eli-
gible nonresponders.
Results: Participants had better self-reported health (p = 0.02), were 
younger, more physically active, higher educated, and more often for-
mer smokers compared with eligible nonresponders (all p < 0.001). 
No differences were seen in self-reported outcomes of pulmonary 
tests, history of lung cancer, and smoked pack-years. Mortality due 
to all-causes (p < 0.001) and mortality classification separately was 
lower among participants. However, the proportion of subjects death 
due to cancer was higher among participants (62.4% vs. 54.9%).
Conclusion: Modest differences in baseline characteristics between 
participants and eligible nonresponders, led to minor differences in 
mortality profiles. However, group sizes were large and therefore it 
seems unlikely that these small differences will influence the gener-
alizability of the NELSON trial. Results of the NELSON trial can 
roughly be used to predict the effect of population-based lung cancer 
screening.
Key Words: Selection bias, Refusal to participate, Mass screening 
and Lung cancer.
(J Thorac Oncol. 2015;10: 747–753)
Lung cancer is a major public health problem worldwide, due to its high incidence and poor 5-year survival rate of 
less than 15%.1 Smoking cessation offers the best prospects for 
reducing the risk of developing lung cancer.2 Although smok-
ing prevalence is decreased in Europe,3 the residual effects 
of smoking on lung cancer risk remains notable in former 
smokers and a significant proportion of lung cancers are now 
diagnosed in former smokers.4,5 For this group, primary pre-
vention is not meaningful. However, if lung cancer is detected 
in an early stage, treatment options are generally more prom-
ising.6 The National Lung Screening Trial demonstrated that 
computed tomography (CT) screening can reduce lung cancer 
mortality by 20% compared with chest radiography.7 In the 
United States, this finding has led the United States Prevention 
Service Task Force to recommend lung cancer screening for 
current and former smokers, if quit within the past 15 years, 
aged 55 through 80 years with a smoking history of at least 
30 pack-years.8 However, many issues remain regarding the 
technical and logistical aspects of screening, cost–effective-
ness and generalizability. In Europe, no lung cancer screen-
ing trial has yet demonstrated a significant reduction in lung 
cancer mortality.9–11 However, the largest European trial, the 
Dutch-Belgian lung cancer screening trial (NELSON), is still 
ongoing. The NELSON trial investigates whether screening 
using low-dose CT (LDCT) can reduce lung cancer mortality 
by at least 25% at 10 years of follow-up12, 13. Major differences 
between the NELSON trial and the National Lung Screening 
Trial are that NELSON (1) offers no screening to control 
group participants, (2) has different intervals between screen-
ing rounds, and (3) uses different management protocols 
for nodules and abnormalities.12,14 In interpreting the results 
of screening studies, it is important to know whether study 
participants were representative of the target population, as 
volunteers who are healthier and more concerned about their 
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own health are more willing to participate in screening pro-
grams.15–17 This form of bias may affect the generalizability of 
the study results, as the studied subjects may differ from the 
target population for screening.
So far, previous studies have indicated that participants 
of lung cancer screening studies are younger,16,18,19 less likely to 
be current smokers,15,17,19,20 more physically active and higher 
educated15,18,19 compared with nonparticipants. Other cancer 
screening studies indicated that higher socioeconomic status 
and “healthy lifestyle” predicts screening participation.18,21–24 
Screening trial participants also had lower incidence of can-
cer,15,17 diabetes,15 cardiovascular,15 and respiratory15 diseases, 
than nonparticipants. One pilot study of lung cancer screen-
ing even showed that participants had a lower mortality rate 
for all types of cancer besides lung cancer, cardiovascular 
diseases, and noncancerous diseases other than cardiovascu-
lar and respiratory diseases compared with nonparticipants.16 
However, lung cancer mortality was higher among partici-
pants. This mortality difference might be explained by selec-
tion bias; attendees of screening programs may have more 
awareness of being at risk of developing lung cancer, which 
may increase their interest in screening.16,25
So far, previous research showed that the NELSON 
study population is younger, has a better general health, has 
a higher proportion of current heavy smokers and is slightly 
lower educated compared with the general Dutch population.17 
However, less is known about potential differences in physi-
cal activity, alcohol consumption, smoking-related symptoms, 
the effect on the mortality profile of participants and eligible 
nonparticipants (the so-called eligible nonresponders; Fig. 1).
The aim of this study was to investigate whether differ-
ences in characteristics and mortality profiles of participants 
of the NELSON study, and eligible nonresponders exist. The 
results of this study are relevant for the interpretation of the 
forthcoming mortality analyses of the NELSON trial.
METHODS
NELSON Trial
In the NELSON trial, 15,822 high-risk volunteers were 
randomized (1:1) to screening (n = 7915) using LDCT at 
respectively baseline and 1, 3, and 5.5 years after baseline, 
or to no screening (n = 7909).26 The NELSON study aims to 
investigate whether screening using LDCT can reduce lung 
cancer mortality by at least 25%. The study design and con-
duct were published previously.27–29 The NELSON trial was 
approved by the Dutch Minister of Health after positive advice 
from the Dutch health Council and by the Ethics Boards of the 
participating centers.
Study Population
Population-based recruitments
During the recruitment phase, which occurred in two 
waves (during the second half of 2003 and the second half of 
2005), addresses of subjects aged between 50 and 74 years 
were obtained from the population registries of seven districts 
in the Netherlands and 14 municipalities around Leuven in 
Belgium.28 These subjects received a questionnaire about 
their general health, medical check-ups and history, physi-
cal activity, body weight and length, smoking history, alcohol 
consumption, family history of cancer, education and their 
opinion on screening programs in general.
General health was determined by the subjects “ability to 
climb two flights of stairs” (yes, no, don’t know) and how they 
would describe their health: excellent, very good, good, moder-
ate, or severe. Questions regarding smoking-related symptoms 
of lung disease were: did you have symptoms of coughing/spu-
tum/wheezing/dyspnea for at least 3 months this year? (yes, no).
Questions on medical history and check-ups were as 
follows: was one of the following diagnostic procedures per-
formed last year, 1–5 year, or greater than or equal to 5 years 
ago: (1) chest x-ray, pulmonary function test, CT-scan of the 
chest or sputum test?, (2) did you undergo lung surgery (e.g., 
pneumonectomy or lobectomy)?, (3) were you diagnosed with 
cancer and if so, when (less than 5 years ago, greater than or 
equal to 5 years ago, or greater than or equal to 5 years ago 
and still under treatment)? and (4) what type of cancer were 
you diagnosed with (lung cancer, breast cancer, kidney cancer, 
melanoma, or other type)? Furthermore, physical activity was 
assessed as follows: how many times a week are you physi-
cally active for greater than or equal to 30 minutes (daily, 5–6 
times, 2–4 times, 1 time, or less than 1 time a week). Alcohol 
consumption was assessed by asking how much alcohol was 
consumed at once (in pints) and at which base: daily, 5–6 times 
a week, 3–4 times a week, 1–2 days a week, 1–3 days a month, 
less than 1 glass a month or never. Willingness to participate 
in screening programs was assessed for prostate cancer, colon 
cancer, diabetes, cholesterol and cardiovascular diseases (yes, 
no, do not know) and their opinion on an acceptable number 
of persons to screen to detect one case of lung cancer at early 
stage (10, 100, 1000, 10,000, 100,000, or 1,000,000). The 
highest completed level of education was determined through 
a single question with seven options: primary education, lower 
technical or vocational education, general secondary educa-
tion, secondary technical or vocational education, senior gen-
eral secondary education or pre-university education, higher 
technical or vocational education and university. The ques-
tionnaire also assessed smoking in detail.28,30 Finally, each 
person’s body mass index was calculated (weight/length2).
A total of two recruitment rounds were necessary to 
reach the required number of participants.
The questions of the first questionnaire were slightly 
changed for the second wave using the experience of the first 
response. The overall response rate for the first questionnaire 
was 24.9%.12
Respondents who met the eligibility criteria (n = 
30,051) received an invitation to participate, a second ques-
tionnaire, an information leaflet and informed consent form 
for the NELSON trial.28 The eligibility criteria were as fol-
lows: age 50–75 years, smoking history of greater than or 
equal to 15 cigarettes per day for greater than or equal to 25 
years or greater than or equal to 10 cigarettes for greater than 
or equal to 30 years, and were still smoking or had quit less 
than or equal to 10 years ago. Exclusion criteria were: a mod-
erate or bad self-reported health and inability to climb two 
flight of stairs, a body weight greater than or equal to 140 kg, a 
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history of renal, melanoma or breast cancer, lung cancer diag-
nosed less than 5 years ago or greater than 5 years ago but still 
receiving treatment, or a chest CT examination within the past 
year.28 In addition, the second questionnaire assessed smoking 
habits and exposure to asbestos in more detail.
Eligible responders who provided informed consent and 
completed the second questionnaire (n = 15,822, response rate 
of 51.1%) were randomized (1:1) to either the screen group or 
the control group.
Inclusion in this substudy
For this substudy, subjects randomized to the control 
group (n = 7453) were compared with eligible subjects who 
did not participate (n = 13,661). Subjects randomized to the 
screen group were excluded because of the potential effect of 
screening on their mortality profiles and the embargo on mor-
tality outcomes of this group. Furthermore, this substudy was 
limited to Dutch subjects, as only Dutch mortality data was 
available at the time of analyses.
Mortality Data
Anonymised mortality data for both groups were 
obtained via Statistics Netherlands. January 2013 was chosen 
as end date of this substudy, at which point 99.1% of the sub-
jects were traceable. To obtain mortality data, this study popu-
lation was matched using four variables: sex, date of birth, zip 
code, and date of obtaining addresses. This led to an accuracy 
of almost 98% in matching.
Person-years were calculated as the time between 
obtaining the addresses of the subject and subject’s date of 
death or the end date of this study, whichever came first.
To analyze mortality profiles, we classified the causes of 
death by disease groups, using the International Classification 
of Diseases, 10th edition: all-causes, all cancer causes, car-
diovascular diseases, respiratory diseases, and noncancer dis-
eases other than cardiovascular or respiratory diseases.
Statistical Analyses
Baseline characteristics of control group subjects and 
eligible nonresponders were retrieved from the first question-
naire. Differences in baseline characteristics were assessed 
using the following tests: for continuous variables, normality 
was tested using the Kolmogorov–Smirov test and differences 
between the two groups were assessed by using the Mann–
Whitney U test, as appropriate. For nominal variables, the χ2 
test was used and the Mann–Whitney U test was used for cat-
egorical variables.
Classified mortality data were compared between the 
two groups by using the χ2 test. For all analyses, p values less 
than 0.05 were considered statistically significant. SPSS ver-
sion 21 and STATA 13 special edition were used to perform 
the analyses.
RESULTS
A total of 7453 Dutch control group participants were 
compared with 13,661 Dutch eligible nonresponders (Table 1). 
Participants were younger (p < 0.001), more often male 
(p < 0.001), had better self-reported general health (p = 0.02), 
higher level of physical exercise (p < 0.001) and a higher 
level of education (p < 0.001). Participants also consumed 
more alcohol (p < 0.001) and consisted of higher proportion 
FIGURE 1.  Recruitment of the NELSON study par-
ticipants and the selection for this substudy.
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of former smokers (p < 0.001). However, most differences in 
proportions were small.
Small differences were also seen in smoking-related 
characteristics (Table 2). Smoking duration was lower among 
participants (p < 0.001), whereas numbers of cigarettes 
smoked per day was higher among participants (p < 0.001). 
However, no differences were observed in the number of pack-
years smoked between participants and eligible nonresponders. 
Participants started smoking at a younger age (p < 0.001) and 
were more willing to quit smoking than eligible nonresponders 
(p < 0.001). Among current smokers, participants were 
more often in an advanced stage- according to the stages of 
change- to quit smoking compared with eligible nonresponders 
(p < 0.001). Participants reported significantly more smoking-
related symptoms (p = 0.04) and had undergone a pulmonary 
function test more often (p < 0.001). However, no differences 
were seen in the self-reported outcome of these pulmonary 
function tests (p = 0.28).
During the study period, the all-cause mortality rate 
among eligible nonresponders was higher compared with the 
participants (p < 0.001; Table 3).The eligible nonresponders 
had a higher mortality rate due to all types of cancer 
(p = 0.002), cardiovascular diseases (p < 0.001), respiratory 
diseases (p = 0.018), and noncancerous diseases other than 
cardiovascular or respiratory (p < 0.001). However, the pro-
portion of deaths due to cancer was higher among participants 
(62.4% vs. 54.9%). Higher educational achievement was sig-
nificantly associated with higher mortality from all types of 
cancer (χ2 17.3; p < 0.001). Furthermore, a longer follow-up 
was seen for participants (10 years vs. 9 years).
Participants were significantly more likely to participate 
in any of the mentioned screening programs compared with 
the eligible nonresponders (all p < 0.001, data not shown). The 
median physical distance from home to one of the nearby par-
ticipating screening centers was significantly less for eligible 
nonresponders than for participants (16.9 km versus 17.9 km; 
p = 0.003).
DISCUSSION
This study investigated differences in characteristics 
and mortality profiles of participants of the NELSON trial and 
eligible nonresponders. Results of this study are essential to 
TABLE 1.  Baseline Characteristics of NELSON Control Group Participants and Eligible Nonresponders
Control Group Participants Eligible Nonresponders p Value
Total N = 7453 Total N = 13,661
% n/N % n/N
Age (years): median (IQR) 57.0 (8.0) 7453 58.0 (9.0) 13,661 <0.001
Male 84.2 6275/7453 80.6 11,013/13,661 <0.001
General health 0.02
  Excellent/very good 15.2 1124/7393 14.2 1913/13,477
  Good 66.6 4922/7393 66.7 8984/13,477
  Moderate/poor 18.2 1347/7393 19.1 2580/13,477
Physical exercisea <0.001
  High 44.5 3292/7398 48.5 6533/13,459
  Moderate 44.8 3318/7398 39.8 5354/13,459
  Low 10.7 788/7398 11.7 1572/13,459
BMI: median (IQR) 25.9 (4.2) 7177/7453 25.8 (4.4) 12,932/13,661 0.16
Education levelb <0.001
  Lowest 11.0 806/7352 18.1 2410/13,339
  Low 37.4 2750/7352 41.4 5530/13,339
  Medium 23.3 1712/7352 20.6 2750/13,339
  High 28.3 2084/7352 19.9 2649/13,339
Alcoholc: median (IQR) 15.7 (83.9) 6754/7453 13.8 (83.9) 11,705/13,661 <0.001
Smoker status <0.001
  Current smoker 54.8 4077/7434 60.4 8196/13,578
  Former smoker 45.2 3357/7434 39.6 5382/13,578
History of lung cancer 4.7 344/7396 4.4 594/13,502 0.40
Person-years of observation: median (IQR) 10.0 (2.0) 7453 9.0 (2.0) 13,661 <0.001
Data were presented as % (n/N) unless stated otherwise.
aPhysical activity: high was defined as greater than or equal to 5 times active for greater than or equal to 30 minutes a week, moderate was defined as greater than or equal to 1 but 
less than 5 times active for greater than or equal to 30 minutes a week and low was defined as less than 1 time active for greater than or equal to 30 minutes a week.
bEducation level: lowest: only elementary; low education: Lower technical or vocational education and general secondary education; medium education level: secondary technical 
or vocational education and senior general secondary education; high education level: higher technical or vocational education and university.
cAlcohol consumption in glasses per week.
BMI, body mass index.
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determine whether mortality results of the NELSON trial are 
generalizable to the target Dutch population for lung cancer 
screening.
Participants of the NELSON trial were significantly 
younger, had better self-reported health, were more physically 
active, and higher educated compared with eligible nonre-
sponders, although the differences in proportions were mod-
est. These results are in line with previous studies in cancer 
screening trials15, 16, 18, 19. Furthermore, men were more likely 
to participate in the NELSON trial, whereas more women par-
ticipated in the Danish Lung cancer Screening Trial (DLST).18 
Different recruitments methods may explain the differences 
in study populations between NELSON trial and DLST: 
the NELSON trial was designed to recruit only men at first, 
because of fewer Dutch women met the smoking-related inclu-
sion criteria of the NELSON study. However, in the second 
recruitment women were also invited to allow the NELSON 
study results to be generalizable to women. In contrast, the 
DLST recruited both sexes from the start of the study. Such 
overrepresentation of women participating in screening trials 
is also seen by others and may be because women are more 
used to screening from other cancer screening programs.31
TABLE 2.  Smoking-Related Characteristics of NELSON Control Group Participants and Eligible Nonresponders
Control Group Participants Eligible Nonresponders p Value
Total N = 7453 Total N = 13,661
% n/N % n/N
Pack-years: median (IQR) 37.9 (19.8) 37.9 (21.5) 0.07
Smoking duration <0.001
  ≤35 yrs 38.2 2838/7437 35.7 4859/13,594
  36–40 yrs 31.8 2363/7437 30.4 4136/13,594
  41–45 yrs 19.5 1451/7437 20.7 2816/13,594
  >45 yrs 10.5 785/7437 13.1 1783/13,594
No. of cigarettes smoked per day <0.001
  ≤15 22.1 1642/7439 24.2 3282/13,604
  16–20 28.3 2101/7439 29.5 4016/13,604
  21–25 26.8 1994/7439 25.3 3444/13,604
  26–30 11.0 822/7439 9.4 1283/13,604
  31–40 6.9 513/7439 7.1 965/13,604
  >40 4.9 367/7439 4.5 614/13,604
Starting age of smoking <0.001
  ≤14 yrs, n (%) 16.0 1189/7422 15.0 2000/13,537
  15–19 yrs, n (%) 65.0 4845/7422 64.0 8718/13,537
  20–24 yrs, n (%) 16.0 1184/7422 17.0 2338/13,537 
  >25 yrs, n (%) 3.0 204/7422 4.0 481/13,537
Motivated to quit smokinga 93.3 4854/5201 91.4 7555/8269 <0.001
Stage of changeb <0.001
  Precontemplation phase 33.2 1725/5201 39.3 3249/8269
  Contemplation phase 14.1 736/5201 13.7 1129/8269
  Preparation 7.3 379/5201 7.5 621/8269
  Action 4.7 244/5201 4.3 359/8269
  Maintenance 40.7 2117/5201 35.2 2911/8269
Smoking-related symptomsc 0.04
  Yes, ≥1 53.8 2777/5157 52.0 4279/8229
Spirometry
  Yes 59.2 2978/5029 53.2 4186/7873 <0.001
Result of spirometryd 0.28
  Normal (%) 81.3 1867/2296 82.5 2522/3058
  Abnormal (%) 18.7 429/2296 17.5 536/3058
Data were presented as % (n/N) unless stated otherwise.
aMotivated to quit smoking: comparison between subjects who are current smokers only.
bStage of change: precontemplation phase: does not want to stop, wants to stop but not in the next 5 years, wants to stop but not in the next year, wants to stop but not in the next 6 
months. Contemplation phase: wants to stop in the next 6 months. Preparation: wants to stop in the next 1 month. Action: stopped less than 6 months ago. Maintenance: stopped greater 
than 6 months ago.
cSmoking-related symptoms: coughing, sputum, dyspnea, and wheezing.
dSpirometry: comparison between subjects with spirometry only.
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In the NELSON study, number of pack-years smoked 
between the two groups was similar, but participants were 
more often former smokers.17 This is in contrast with the 
DLST and an Italian lung cancer screening trial, in which cur-
rent smokers were overrepresented.16,18 However, the DLST 
also reported that despite active smoking, participants were 
more willing to quit smoking than nonparticipants (a repre-
sentative sample from the Danish population), suggesting that 
smokers who are motivated to quit smoking are more inclined 
to volunteer in a screening trial.18
Eligible nonresponders had a higher all-cause mortal-
ity and mortality due to four other mortality classifications. 
However, the relative proportion of subjects that died due to 
all types of cancer was higher among participants. This might 
be explained by alcohol abuse, which is associated with higher 
socioeconomic status, e.g., higher educational achievement.32 
Higher alcohol consumption is associated with a higher rela-
tive risk for death from cancer.33 Another explanation might 
be that participants reported more smoking-related symptoms, 
which may have led to more general practitioner consults. 
This may have led to the higher proportion of former smokers 
among participants and could have facilitated the detection of 
cancer, cardiovascular, and respiratory diseases. This may have 
resulted in early treatment of smoking-related diseases among 
NELSON participants and may have led to lower mortality 
rates compared with eligible nonresponders. However, the 
slightly younger age, better self-reported health, and healthier 
lifestyle among participants may have had a bigger contribu-
tion to these differences in mortality profiles and resulted in a 
significantly longer follow-up among participants.
As mentioned, participants were more likely to partici-
pate in any of the mentioned screening programs compared 
with the eligible nonresponders. Higher education levels may 
have led to more awareness of their risk for lung cancer and 
influenced the decision to participate in the NELSON trial. In 
addition, there were more former smokers among participants. 
It has been previously reported that active smoking is a barrier 
to participate in screening for lung cancer.20,34 Notable, living 
further from participating screening center, participants in the 
NELSON trial were more willing to participate than the eli-
gible nonresponders. In contrast, the Lung-SEARCH screen-
ing trial reported that half of the responders found inability to 
travel the most significant reason not to participate.25
The main strengths of this study are: (1) the large num-
ber of participants and eligible nonresponders, (2) access to 
all the completed first questionnaires of subjects, (3) the 
availability of mortality data from Statistics Netherlands, 
and (4) a long follow-up duration of 10 years. Finally, so 
far no large lung screening trial using LDCT has studied 
the differences in baseline characteristics and potential 
effect on mortality profiles between participants and eligible 
nonresponders.
This study was limited by the fact that Statistics 
Netherlands could only provide aggregated mortality data. 
Therefore, it was not possible to perform multivariate analy-
ses. Furthermore, all questionnaire data were self-reported, as 
in other studies.7 The questionnaires included few questions 
on socioeconomic class and no questions on ethnic back-
ground or psychosocial profile.
In conclusion, differences in age, health, lifestyle, and 
socioeconomic class can lead to a healthy participant effect, 
i.e., a different study outcome than would have been observed 
if the characteristics of participants were similar to that of the 
target population. As expected, the distribution of participant 
characteristics in the NELSON study suggest that the study 
population is somewhat younger, healthier (e.g., more physi-
cally active, less current smokers), higher educated and more 
willing to participate in a screening program. These differ-
ences have influenced the mortality outcome of participants 
and eligible nonresponders. But, these differences are mod-
est and therefore it seems unlikely that these differences 
will influence the generalizability of the main results of the 
NELSON trial.
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